Neos Therapeutics Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neos Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Neos Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NEOS, but not buy additional shares or sell existing shares.
View analyst ratings for Neos Therapeutics or view top-rated stocks.

Wall Street analysts have given Neos Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Neos Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Neos Therapeutics saw a decrease in short interest in January. As of January 29th, there was short interest totaling 995,500 shares, a decrease of 34.5% from the January 14th total of 1,520,000 shares. Based on an average trading volume of 5,610,000 shares, the short-interest ratio is presently 0.2 days. Approximately 2.1% of the shares of the company are short sold.
View Neos Therapeutics' Short Interest.

Neos Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, March 12th 2021.
View our earnings forecast for Neos Therapeutics.

Neos Therapeutics, Inc. (NASDAQ:NEOS) posted its quarterly earnings results on Monday, November, 9th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.05. The company earned $12.54 million during the quarter.
View Neos Therapeutics' earnings history.

Neos Therapeutics' stock was trading at $1.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NEOS shares have decreased by 29.6% and is now trading at $0.9713.
View which stocks have been most impacted by COVID-19.

10 employees have rated Neos Therapeutics CEO Mark Tengler on Glassdoor.com. Mark Tengler has an approval rating of 26% among Neos Therapeutics' employees. This puts Mark Tengler in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Neos Therapeutics include Heat Biologics (HTBX), AcelRx Pharmaceuticals (ACRX), Sol-Gel Technologies (SLGL), vTv Therapeutics (VTVT), Kindred Biosciences (KIN), Assembly Biosciences (ASMB), Aquestive Therapeutics (AQST), FS Development (FSDC), Enochian Biosciences (ENOB), Lantern Pharma (LTRN), Seelos Therapeutics (SEEL), DiaMedica Therapeutics (DMAC), Orgenesis (ORGS), Clearside Biomedical (CLSD) and GlycoMimetics (GLYC).
View all of NEOS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neos Therapeutics investors own include Verastem (VSTM), SCYNEXIS (SCYX), TherapeuticsMD (TXMD), TG Therapeutics (TGTX), AcelRx Pharmaceuticals (ACRX), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL), Progenics Pharmaceuticals (PGNX), T2 Biosystems (TTOO) and Agile Therapeutics (AGRX).

(NEOS) raised $60 million in an initial public offering on Thursday, July 23rd 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

Neos Therapeutics trades on the NASDAQ under the ticker symbol "NEOS."

Neos Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Stonepine Capital Management LLC (9.97%), Renaissance Technologies LLC (2.16%) and Virtu Financial LLC (0.08%).
View institutional ownership trends for Neos Therapeutics.

NEOS stock was bought by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC, Renaissance Technologies LLC, and Virtu Financial LLC.
View insider buying and selling activity for Neos Therapeutics or or view top insider-buying stocks.

Shares of NEOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NEOS stock can currently be purchased for approximately $0.97.

Neos Therapeutics has a market capitalization of $48.33 million and generates $64.65 million in revenue each year. The company earns $-16,900,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

Neos Therapeutics employs 213 workers across the globe.

The official website for Neos Therapeutics is www.neostx.com.

Neos Therapeutics is headquartered at 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050.

Neos Therapeutics' mailing address is 2940 NORTH HIGHWAY 360, GRAND PRAIRIE TX, 75050. The company can be reached via phone at 972-408-1300 or via email at [email protected]